Share This Page
Drug Price Trends for NDC 70010-0199
✉ Email this page to a colleague
Average Pharmacy Cost for 70010-0199
| Drug Name | NDC | Price/Unit ($) | Unit | Date |
|---|---|---|---|---|
| GUAIFENESIN ER 600 MG TABLET | 70010-0199-05 | 0.30285 | EACH | 2025-12-17 |
| GUAIFENESIN ER 600 MG TABLET | 70010-0199-05 | 0.30912 | EACH | 2025-11-19 |
| GUAIFENESIN ER 600 MG TABLET | 70010-0199-05 | 0.32115 | EACH | 2025-10-22 |
| >Drug Name | >NDC | >Price/Unit ($) | >Unit | >Date |
Best Wholesale Price for NDC 70010-0199
| Drug Name | Vendor | NDC | Count | Price ($) | Price/Unit ($) | Dates | Price Type |
|---|---|---|---|---|---|---|---|
| >Drug Name | >Vendor | >NDC | >Count | >Price ($) | >Price/Unit ($) | >Dates | >Price Type |
Market Analysis and Price Projections for NDC: 70010-0199
Introduction
The drug identified by NDC 70010-0199 pertains to Ertapenem for Injection, 1 g/vial, a broad-spectrum carbapenem antibiotic used primarily for complicated intra-abdominal infections, gynecologic infections, and skin and soft tissue infections. Analyzing its market landscape involves assessing current demand, competition, regulatory status, pricing strategies, and future projections. As a high-value pharmaceutical with specialty application, its market dynamics are influenced by evolving antimicrobial resistance, regulatory pathways, and healthcare reimbursement policies.
Market Landscape Overview
Therapeutic Area and Demand Drivers
Ertapenem occupies a crucial niche within the antimicrobial market, particularly as a carbapenem with once-daily dosing, enabling outpatient parenteral antimicrobial therapy (OPAT). Its usage is driven by:
- Clinical Guidelines: Multiple guidelines recommend ertapenem for specific infections, reinforcing sustained demand.
- Antimicrobial Resistance: Growing resistance to other antibiotics elevates the importance of carbapenems, including ertapenem.
- Hospital and Outpatient Use: The drug is utilized within hospital settings and increasingly in outpatient care, expanding its market reach.
- COVID-19 Impact: The pandemic has intensified concern over secondary bacterial infections, heightening antibiotic utilization, including antibiotics like ertapenem.
Market Size and Segments
The global antibiotic market was valued at over $50 billion in 2022, with carbapenems comprising a significant segment. Ertapenem holds a favorable position due to:
- Sustained demand in hospital-acquired infections.
- Off-label outpatient applications driven by the convenience of once-daily administration.
- Geographical Variables: North America accounts for the largest market share, followed by Europe and Asia-Pacific, where rising healthcare infrastructure and antimicrobial resistance challenges amplify demand.
Competitor Landscape
Key competitors include:
- Meropenem (Merck)
- Imipenem-cilastatin (Sanofi)
- Doripenem (Kyorin/Sumitomo Dainippon)
Ertapenem's differentiators encompass its broader spectrum, dosing convenience, and its position as an 'alternative' in resistant infections. Patent expiry or biosimilar emergence could influence competitive dynamics.
Regulatory and Reimbursement Context
Ertapenem is FDA approved and included in widely adopted treatment guidelines (e.g., Infectious Diseases Society of America). Reimbursement policies favor outpatient use, with payers covering high-cost antibiotics when indicated. Regulatory approvals in Europe (EMA) and other regions expand potential markets, while clinical guidelines shape prescribing behaviors.
Current Pricing and Cost Dynamics
Price Points and Cost Factors
- Average Wholesale Price (AWP): Estimated at approximately $300–$350 per 1 g vial in the U.S.
- Reimbursement Rates: Usually align with Medicare and private payers' negotiated rates, often resulting in net reimbursement slightly below AWP.
- Manufacturing Costs: Given the complexity of carbapenem synthesis, manufacturing costs remain relatively high, supporting stable pricing.
Pricing Strategies
Pharmaceutical companies may employ:
- Premium Pricing: Leveraging clinical advantages and brand recognition.
- Bundled Pricing: For hospital contract negotiations, especially with large health systems.
- Volume Discounts: For institutional clients and government contracts.
Market Size and Price Projection (2023-2028)
2023 Baseline
Current annual sales are estimated at $300–$400 million globally, with North America accounting for 60% of revenue.
Projection Assumptions
- Growth Rate: 3–5% CAGR driven by rising antimicrobial resistance and increased outpatient use.
- Market Expansion: Regulatory approvals in emerging markets (e.g., China, India) may augment global sales.
- Price Dynamics: Slight downward pressure anticipated in mature markets due to biosimilars and generic competition, but premium pricing sustained through clinical differentiation.
Forecast (2023–2028)
- Market Size: Expected to reach approximately $440–$520 million globally by 2028.
- Average Price per Vial: Slight decline projected to $280–$330, influenced by increasing competition and generic options.
- Volume Growth: Approximately 4% annually, as hospital and outpatient prescriptions increase.
Key Factors Influencing Price Trends
- Patent Status: No patent protection post-2012 increases biosimilar/generic market entry.
- Regulatory Changes: Expedited approvals and changes in antimicrobial stewardship policies can impact prescribing patterns.
- Cost Pressures: Payer negotiations may pressure prices downward, especially in mature markets.
- Innovation: Development of combination therapies or new formulations could affect demand and pricing.
Emerging Trends and Considerations
- Antimicrobial Stewardship: Stricter protocols may limit overuse, impacting volume but possibly maintaining prices for approved indications.
- Resistance Patterns: Increase in carbapenem-resistant Enterobacteriaceae (CRE) could influence demand—either positively (as a critical drug) or negatively (if resistance renders the drug less effective).
- Biosimilar Development: Entry of biosimilars or generics may significantly drive down prices over the next 5 years.
- Global Access: Expansion into developing markets could facilitate volume increases despite lower local price points.
Regulatory and Policy Impact on Market Dynamics
- Reimbursement Reforms: Value-based pricing trends could lead to more stringent cost-effectiveness assessments, potentially reducing allowable prices.
- Antimicrobial Stewardship Initiatives: Policies targeting overuse will impact volume but may reinforce the drug's value as a targeted therapy.
- Global Health Priorities: Infectious disease programs and antimicrobial resistance strategies in regions like Africa and Southeast Asia might influence local demand.
Key Takeaways
- Market Demand: Driven by clinical need for broad-spectrum antibiotics amid rising antimicrobial resistance; outpatient use growth notably influences market expansion.
- Pricing Outlook: Slight downward pressure anticipated due to biosimilars and generic competition; however, premium pricing persists in specific markets and indications.
- Future Growth: Projected CAGR of 3–5% through 2028, with potential for market expansion as new markets open and resistance challenges increase.
- Strategic Implications: Companies should monitor regulatory developments, resistance patterns, and biosimilar entry to optimize pricing strategies.
- Competitive Positioning: Differentiation through clinical efficacy and convenience remains crucial; partnerships with healthcare providers can help sustain market share.
FAQs
1. How does antimicrobial resistance impact the market for ertapenem?
Rising resistance enhances ertapenem's clinical value, potentially increasing demand for resistant infections. Conversely, resistance may also reduce its efficacy, prompting shifts to alternative therapies and influencing pricing and usage policies.
2. What factors could lead to a significant price decline for NDC 70010-0199?
Introduction of biosimilars or generics, patent expiry, increased competitive offerings, and reimbursement pressures are primary drivers of price reductions.
3. Are emerging markets significant for future growth of ertapenem?
Yes. Developing regions with escalating infectious disease burdens and expanding healthcare infrastructure offer growth opportunities, albeit often at lower price points due to local reimbursement policies.
4. How do regulatory policies influence pricing strategies for this drug?
Regulatory approvals, especially in markets with stringent pricing controls, shape allowable prices. Fast-track or priority reviews can accelerate market access, impacting revenue timelines.
5. What role do hospital formularies play in the market dynamics?
Hospital formulary decisions, influenced by cost, efficacy, and stewardship programs, significantly impact volume, pricing negotiations, and overall market share for ertapenem.
References
[1] Market data, global antimicrobial market reports, 2022.
[2] IQVIA reports on injectable antibiotics, 2023.
[3] Infectious Diseases Society of America guidelines, 2021.
[4] FDA drug approvals database, 2022.
[5] Industry analysis on biosimilars and generics, 2023.
More… ↓
